TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Comparison

503A vs 503B Compounding

Same fields, same evidence rules, both sides. No preselected winner.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.

Answer last reviewed:
Approved product against compounded preparation
Approved product against compounded preparation
AttributeFDA-approved tirzepatide (Zepbound, Mounjaro)Compounded tirzepatide
Regulatory statusApproved finished drug productNot an FDA-approved product
Generic equivalentNo generic tirzepatide existsNot a generic and not therapeutically equivalent
Manufacturing standardManufactured under CGMPDepends on the compounder's registration class
Clinical trial evidenceStudied in the registration trialsTrials studied the approved product, not this preparation
LabellingFDA-approved labellingSupplied by the compounder
PresentationManufacturer's pens or vialsVaries; multi-dose vials add a measuring step
Price read on the seller’s own page——

A dash means no figure held. How we grade evidence.

No provider may describe a compounded preparation as FDA-approved or as generic Zepbound. Both statements are false, and both are common.
503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review
503A pharmacy against 503B outsourcing facility
Requirement503A compounding pharmacy503B outsourcing facility
Compounds pursuant toA prescription for an identified individual patientMay compound without patient-specific prescriptions
FDA registrationNot registered as an outsourcing facilityRegisters with FDA
CGMP requirementsNot required to meet CGMPMust comply with CGMP — though registration alone is not evidence of compliance
Primary oversightState board of pharmacyFDA, on a risk-based inspection schedule
Adverse-event reportingNot required under 503ARequired to report adverse events to FDA
Product approval statusNot an FDA-approved productNot an FDA-approved product
What registration establishesNot applicableFDA received the required information, nothing more Verified
Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.
Official verification routescaptured 2026-07-26

Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.

Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Where the cost difference actually sits
MedicationOption A — not capturedOption B — not capturedRequired feesOption A — not capturedOption B — not capturedTwelve-month totalOption A — not capturedOption B — not capturedOption AOption B
Show this figure as a table
Data table
ItemOption AOption B
Medicationnot capturednot captured
Required feesnot capturednot captured
Twelve-month totalnot capturednot captured
Filled from captured records. An empty bar is a gap in our research, not a zero.

The short version

A 503A pharmacy is a state-licensed pharmacy that compounds for individual patients against a prescription. A 503B outsourcing facility registers with FDA, must follow current good manufacturing practice (CGMP), is inspected by FDA on a risk basis, and can make larger batches without a prescription for each unit. Both routes are set out in the Federal Food, Drug, and Cosmetic Act, in section 503A and section 503B.

For tirzepatide, the practical difference is legal footing. A 503A pharmacy can compound from the drug substance for a named patient, within limits on copying approved products. For 503B, FDA proposed on April 30, 2026 not to place tirzepatide on the bulks list that outsourcing facilities compound from. Comments closed July 30, 2026, and no final decision had been published by November 9, 2026. Neither route produces an FDA-approved product.

Where they actually differ

503A pharmacy503B outsourcing facility
Main overseerState board of pharmacyFDA registration and inspection, plus state rules
Manufacturing standardPharmacy compounding standards, not CGMPCGMP
PrescriptionNeeded for each identified patientNot needed for each unit; can supply clinics
Reporting to FDANo routine product reportsReports what it makes twice a year, plus adverse event reports
Source of tirzepatideDrug substance allowed, but not routinely making copies of an approved productDepends on the 503B bulks list; FDA proposed excluding tirzepatide

FDA keeps a list of registered outsourcing facilities. A 503A pharmacy is checked through the board of pharmacy in its home state.

Where they are more similar than claimed

  • Neither is FDA-approved. FDA does not review the safety or effectiveness of tirzepatide made by either kind of compounder.
  • Both make sterile injections. Both need clean-room technique, and contamination is a risk for both.
  • Both get warning letters. FDA enforcement reaches both kinds of compounder. One recent example is warning letter 738238 to Empower Pharmacy, dated September 18, 2026. See our FDA warning letters tracker.
  • The vial in your fridge looks the same. It is usually a multi-dose vial with a concentration on the label, and FDA's 28-day discard rule applies after first use.
  • The class is not a quality grade. "503B" does not guarantee a given vial, and "503A" does not make one unsafe. Inspection history, licence status and testing disclosures tell you more. Our methodology scores whether a provider names its pharmacy, under pharmacy transparency (15 points).

Cost, all-in

You rarely see the pharmacy's price. You pay the telehealth program, which bundles the clinician, the prescription and the pharmacy fill. So the comparison that matters is between programs, with the pharmacy named.

Across the price index read on October 15, 2026, 33 compounded tirzepatide programs ranged from $69 to $299 a month all-in, with a median of $149. Pharmacy class is not listed on most sellers' price pages, so we cannot say whether it predicts price.

One example: NexLife names three state-licensed 503A pharmacies (Absolute Pharmacy in Lutz, Florida; Premium Compounding in Decatur, Alabama; Boudreaux's New Drug Store in Lake Charles, Louisiana). It charges $129 a month month to month, or $115 a month on a 12-month plan, at every dose with no membership (read November 6, 2026).

Check what the price leaves out: shipping, syringes, membership and dose surcharges. Also check vial size. Medicine left after the 28-day discard date is money lost. See the price index and the pharmacy disclosure register.

Who each option suits

Patients rarely choose the pharmacy class. The program does. These checks help whichever class you end up with:

  • Your program uses a 503A pharmacy. Check its licence with the board of pharmacy in its home state. Then check that it is allowed to ship to your state, which often needs a separate non-resident licence.
  • Your program uses a 503B facility. Look it up on FDA's outsourcing facility list. Ask how it is supplying tirzepatide while the bulks-list decision is pending.
  • Your program will not name its pharmacy. That is a bigger warning sign than either class. Our pharmacy verification tool walks through what to ask.
  • You want a product made under CGMP and approved by FDA. Only the brand product is both. See Zepbound vs compounded tirzepatide.

None of this is a recommendation for your treatment.

What the evidence does not settle

  • Quality by class. No published study compares potency, sterility failures or patient harm between 503A and 503B tirzepatide.
  • Whether inspection prevents harm. FDA inspects 503B facilities, but whether that leads to fewer adverse events with compounded GLP-1s specifically has not been shown.
  • The 503B outcome. FDA proposed excluding tirzepatide from the 503B bulks list (91 FR 23431). Comments closed July 30, 2026 (91 FR 38719). A Federal Register search on November 9, 2026 found no final decision.
  • How copying limits are enforced. 503A pharmacies may not routinely make copies of an approved product. How that limit is applied to tirzepatide, pharmacy by pharmacy, is not documented in public.
  • Independent testing. Most test results come from the pharmacy or a lab it picked. Independent batch testing is rarely published.

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Questions readers actually ask

Which one is better?

Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.

Is one of these sponsoring this page?

No. No provider can buy a score, a placement or a review on this site.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “503A vs 503B Compounding.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compare/503a-vs-503b/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4